← Leaderboards
Peter H King
Birmingham Va Medical Center
$4,254,785
Attributed
$4,524,903
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $743.1K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,524,903 · 6
VA$0 · 6
By mechanism
R01$3,352,101 · 3
R21$1,172,802 · 3
I01$0 · 6
Top collaborators
- Shaida A. Andrabi1 shared
Others in their field
Top investigators on “Untranslated Regions”
- Manolis Kellis · Massachusetts Institute Of Technology$24,216,684
- Bing Ren · Ludwig Institute For Cancer Research$21,291,689
- Panagiotis Roussos · Icahn School Of Medicine At Mount Sinai$18,645,014
- Nenad Sestan · Yale University$18,340,124
- Michael P Snyder · Yale University$17,452,363
- Effie W Petersdorf · Fred Hutchinson Cancer Research Center$17,433,572
Research focus
Untranslated RegionsLinkMolecularElementsCessation Of LifeRegulationAmyotrophic Lateral SclerosisDegenerative DisorderMouse ModelResponseRna-Binding ProteinsProteinsCellsMuscleMessenger RnaNeurodegenerative DisordersPathway InteractionsPlayInvestigationProduction3&AposMotor Neuron DiseasePhenotypeAttenuated
Grant awards (35)
Targeting Glial HuR to Suppress Inflammation and Promote Neuroprotection in Acute Stroke$540,236
R01 · FY2025 · NS · contact PI
RNA regulation of inflammatory mediators in glial cells: a novel therapeutic target for neuropathic pain after nerve injury$0
I01 · FY2025 · VA · contact PI
Sustained Smad signaling in ALS muscle promotes disease progression through a dysregulated miRNA transcriptome$0
I01 · FY2025 · VA · contact PI
Therapeutic benefit of targeting neuroinflammation in spinal cord injury with a novel small molecule inhibitor of the RNA regulator HuR$0
I01 · FY2025 · VA · contact PI
Sustained Smad signaling in ALS muscle promotes disease progression through a dysregulated miRNA transcriptome$0
I01 · FY2024 · VA · contact PI
Therapeutic benefit of targeting neuroinflammation in spinal cord injury with a novel small molecule inhibitor of the RNA regulator HuR$0
I01 · FY2024 · VA · contact PI
RNA regulation of inflammatory mediators in glial cells: a novel therapeutic target for neuropathic pain after nerve injury$0
I01 · FY2024 · VA · contact PI
Therapeutic benefit of targeting neuroinflammation in spinal cord injury with a novel small molecule inhibitor of the RNA regulator HuR$0
I01 · FY2023 · VA · contact PI
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression$0
I01 · FY2022 · VA · contact PI
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression$0
I01 · FY2021 · VA · contact PI
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS$321,563
R01 · FY2020 · NS · contact PI
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression$0
I01 · FY2020 · VA · contact PI
FGF23: a novel biomarker in ALS and more$421,545
R21 · FY2019 · NS · contact PI
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS$321,563
R01 · FY2019 · NS · contact PI
Role of Microglial Hur in promoting neuroinflammation and ALS disease progression$0
I01 · FY2019 · VA · contact PI
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS$321,563
R01 · FY2018 · NS · contact PI
HuR and RNA regulation as a Novel Therapeutic Target in Malignant Glioma$0
I01 · FY2018 · VA · contact PI
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS$321,563
R01 · FY2017 · NS · contact PI
HuR and RNA regulation as a Novel Therapeutic Target in Malignant Glioma$0
I01 · FY2017 · VA · contact PI
Smad Signaling in Skeletal Muscle as a Biomarker of Disease Progression in ALS$321,563
R01 · FY2016 · NS · contact PI
HuR and RNA regulation as a Novel Therapeutic Target in Malignant Glioma$0
I01 · FY2016 · VA · contact PI
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue$0
I01 · FY2015 · VA · contact PI
HuR and RNA regulation as a Novel Therapeutic Target in Malignant Glioma$0
I01 · FY2015 · VA · contact PI
Molecular Signatures of Amyotrophic Lateral Sclerosis in Skeletal Muscle$181,912
R21 · FY2014 · NS · contact PI
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue$0
I01 · FY2014 · VA · contact PI
Molecular Signatures of Amyotrophic Lateral Sclerosis in Skeletal Muscle$220,438
R21 · FY2013 · NS · contact PI
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue$0
I01 · FY2013 · VA · contact PI
RNA-Targeted Dysregulation of Survival Factors in ALS: HuR to the Rescue$0
I01 · FY2012 · VA · contact PI
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing$289,168
R01 · FY2011 · NS · contact PI
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing$282,614
R01 · FY2010 · NS · contact PI
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing$17,580
R01 · FY2010 · NS · contact PI
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing$307,344
R01 · FY2009 · NS · contact PI
The Role of HuR in mutant SOD1 dysregulation of VEGF mRNA Processing$307,344
R01 · FY2008 · NS · contact PI
Aberrant VEGF RNA Stability in Amyotrophic Lateral Sclerosis$158,594
R21 · FY2008 · NS · contact PI
Aberrant VEGF RNA Stability in Amyotrophic Lateral Sclerosis$190,313
R21 · FY2007 · NS · contact PI